|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
34,166 |
46,743 |
69,684 |
82,132 |
| Total Sell Value |
$602,180 |
$716,467 |
$925,403 |
$1,081,499 |
| Total People Sold |
3 |
3 |
3 |
4 |
| Total Sell Transactions |
9 |
13 |
21 |
37 |
| End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-05-02 |
4 |
S |
$11.75 |
$12,902 |
D/D |
(1,098) |
17,151 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,924 |
4,063 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
962 |
962 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,886 |
2,886 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,206 |
18,249 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-01-10 |
4 |
AS |
$27.14 |
$32,568 |
D/D |
(1,200) |
1,286 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2022-01-10 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-01-03 |
4 |
AS |
$28.96 |
$52,939 |
D/D |
(1,828) |
14,197 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2022-01-03 |
4 |
OE |
$7.26 |
$16,570 |
D/D |
1,828 |
16,025 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-12-10 |
4 |
AS |
$29.04 |
$34,848 |
D/D |
(1,200) |
1,286 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-12-10 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-12-01 |
4 |
AS |
$29.13 |
$11,652 |
D/D |
(400) |
14,197 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-12-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-11-10 |
4 |
AS |
$32.38 |
$38,856 |
D/D |
(1,200) |
1,286 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-11-10 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-11-01 |
4 |
AS |
$33.24 |
$13,296 |
D/D |
(400) |
14,197 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-11-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-10-27 |
4 |
AS |
$35.00 |
$14,000 |
D/D |
(400) |
14,197 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-10-27 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-10-27 |
4 |
AS |
$35.25 |
$28,200 |
D/D |
(800) |
1,286 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-10-27 |
4 |
OE |
$1.86 |
$1,488 |
D/D |
800 |
2,086 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-10-11 |
4 |
AS |
$27.36 |
$32,832 |
D/D |
(1,200) |
1,286 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-10-11 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-10-01 |
4 |
AS |
$29.92 |
$11,968 |
D/D |
(400) |
14,197 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-10-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
184 Records found
|
|
Page 4 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
